Leerink Partnrs Has Pessimistic View of AxoGen Q4 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Research analysts at Leerink Partnrs lowered their Q4 2025 EPS estimates for AxoGen in a report released on Monday, July 14th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings per share of $0.01 for the quarter, down from their previous forecast of $0.02. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group decreased their price objective on shares of AxoGen from $26.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.50.

AxoGen Price Performance

Shares of NASDAQ AXGN opened at $11.82 on Wednesday. The firm has a market capitalization of $538.28 million, a P/E ratio of -78.79 and a beta of 1.04. AxoGen has a one year low of $7.34 and a one year high of $21.00. The company’s fifty day moving average is $10.94 and its two-hundred day moving average is $15.19. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.65 and a current ratio of 4.28.

Insider Transactions at AxoGen

In other AxoGen news, Director Joseph A. Tyndall sold 20,062 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $11.20, for a total value of $224,694.40. Following the completion of the sale, the director owned 15,345 shares of the company’s stock, valued at $171,864. This trade represents a 56.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.78% of the company’s stock.

Institutional Trading of AxoGen

Hedge funds have recently made changes to their positions in the stock. US Bancorp DE acquired a new stake in shares of AxoGen during the fourth quarter worth approximately $30,000. State of Wyoming bought a new position in AxoGen during the fourth quarter worth $31,000. Fifth Third Bancorp bought a new position in AxoGen during the first quarter worth $92,000. Harvest Fund Management Co. Ltd bought a new position in AxoGen during the fourth quarter worth $93,000. Finally, GAMMA Investing LLC lifted its stake in AxoGen by 3,884.6% during the first quarter. GAMMA Investing LLC now owns 5,698 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 5,555 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.